Categories: All postsAnalysts

It’s a good time to buy Kinaxis stock, Laurentian Bank Financial says

Kinaxis CEO John Sicard

Kinaxis (Kinaxis Stock Quote, Chart TSX:KXS) remains a high quality top line growth story, says Laurentian Bank Securities analyst Nick Agostino who in a Thursday action note to clients reiterated his “Buy” recommendation and target price of C$105.00.

for KXS, representing a projected return of 18.1 per cent at the time of publication.

Ahead of Kinaxis’ third quarter financials on November 9, Agostino expects KXS to generate in-line results on sales at $39.5 million, EBITDA of $10.5 million and adj. EPS of $0.23 (all figures in US dollars unless otherwise noted). Drilling down, the analyst is looking for subscription sales of $28.4 million with the company ending Q3 with $175.0 million in net cash.

Agostino says that he’ll be focusing on three main items driving his growth expectations: (1) continued momentum in Kinaxis’ Life Sciences/Autos segments; (2) market penetration in consumer packaged goods; and (3) increased penetration into a new vertical, viz. process manufacturing.

“From our observations at the User Conference, we believe Life Sciences, CPG, High Tech, and Food & Beverage remain solid growth areas for KXS based on client and prospect attendees/feedback,” says Agostino.

The analyst bases his target price on a 9x his 2019/2020 sales estimate valuation.

“As witnessed in the past, management has a track record of raising guidance as the year plays out, and as contract visibility improves. Given the momentum evident at the User Conference and the upped guidance in Q2, we see a similar potential as 2018 firms up,” he says. “In light of the recent market sell-off and with KXS’s growth trajectory on solid ground, we believe an attractive entry point is before investors.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: kxs
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

1 day ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

1 day ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

1 day ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago